The cancer biomarker osteopontin: Combination with other markers

Cancer Genomics and Proteomics

Volumn 8, Issue 6, 2011, Pages 263-288

  Weber, Georg F ^a  

^a UNIVERSITY OF CINCINNATI ACADEMIC HEALTH CENTER   (United States)

Author keywords

Biomarker; Cancer; Diagnosis; Osteopontin; Prognosis; Review

Indexed keywords

BIOLOGICAL MARKER; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOPONTIN; PROTEINASE; TUMOR ANTIGEN;

ANGIOGENESIS; BREAST CANCER; CALCIUM HOMEOSTASIS; CANCER DIAGNOSIS; CANCER GROWTH; CELL ADHESION; CELL MOTILITY; CYTOSKELETON; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; EXTRACELLULAR MATRIX; FIBRINOLYSIS; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; KIDNEY TUMOR; LIVER CANCER; LUNG CANCER; MEDICAL DECISION MAKING; MOUTH CANCER; OVARY CANCER; PANCREAS CANCER; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SARCOMA; SKIN CANCER; STOMACH CANCER; THYROID CANCER; TREATMENT RESPONSE;

EID: 81855174717     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Review

References (117)

1. Weber GF, Lett GS and Haubein NC: Osteopontin is a marker for cancer aggressiveness and patient survival. Brit J Cancer 103: 861-869, 2010.
2. Weber GF, Lett GS and Haubein NC: Meta-analysis of osteopontin as a clinical cancer marker. Oncol Rep 25: 433-441, 2011.
3. Ribeiro-Silva A and Oliveira da Costa JP: Osteopontin expression according to molecular profile of invasive breast cancer: a clinicopathological and immunohistochemical study. Int J Biol Markers 23: 154-160, 2008.
4. Kim YW, Park YK, Lee J, Ko SW and Yang MH: Expression of osteopontin and osteonectin in breast cancer. J Korean Med Sci 13: 652-657, 1998. (Pubitemid 128686444)
5. Rudland S, Martin L, Roshanlall C, Winstanley J, Leinster S, Platt-Higgins A, Carroll J, West C, Barraclough R and Rudland P: Association of S100A4 and osteopontin with specific prognostic factors and survival of patients with minimally invasive breast cancer. Clin Cancer Res 12: 1192-2000, 2006.
6. Wang X, Chao L, Ma G, Chen L, Tian B, Zang Y and Sun J: Increased expression of osteopontin in patients with triple-negative breast cancer. Eur J Clin Invest 38: 438-446, 2008. (Pubitemid 351712928)
7. Mirza M, Shaughnessy E, Hurley JK, Vanpatten KA, Pestano GA, He B and Weber GF: Osteopontin-c is a selective marker of breast cancer. Int J Cancer 122: 889-897, 2008.
8. Wang G, Platt-Higgins A, Carroll J, de Silva Rudland S, Winstanley J, Barraclough R and Rudland PS: Induction of metastasis by S100P in a rat mammary model and its association with poor survival of breast cancer patients. Cancer Res 66: 1199-2007, 2006.
9. Martinetti A, Bajetta E, Ferrari L, Zilembo N, Seregni E, Del Vecchio M, Longarini R, La Torre I, Toffolatti L, Paleari D and Bombardieri E: Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole. Endocr Relat Cancer 11: 771-779, 2004. (Pubitemid 40065550)
10. Bellahcène A and Castronovo V: Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. Am J Pathol 146: 95-100, 1995.
11. Reinholz MM, Iturria SJ, Ingle JN and Roche PC: Differential gene expression of TGF-beta family members and osteopontin in breast tumor tissue analysis by real-time quantitative PCR: Breast Cancer Res 74: 255-269, 2002. (Pubitemid 34848353)
12. Sharp JA, Sung V, Slavin J, Thompson EW and Henderson MA: Tumor cells are the source of osteopontin and bone sialoprotein expression in human breast cancer. Lab Invest 79: 869-877, 1999. (Pubitemid 29344499)
13. Ibrahim T, Leong I, Sanchez-Sweatman O, Khokha R, Sodek J, Tenenbaum HC, Ganss B and Cheifetz S: Expression of bone sialoprotein and osteopontin in breast cancer bone metastases. Clin Exp Metastasis 18: 253-260, 2000. (Pubitemid 32269995)
14. Carlinfante G, Vassiliou D, Svensson O, Wendel M, Heinegård D and Andersson G: Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma. Clin Exp Metastasis 20: 437-444, 2003. (Pubitemid 37108430)
15. Singhal H, Bautista DS, Tonkin KS, O'Malley FP, Tuck AB, Chambers AF and Harris JF: Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 3: 605-611, 1997. (Pubitemid 27211840)
16. Fisher JL, Field CL, Zhou H, Harris TL, Henderson MA and Choong PF: Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases - a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases. Breast Cancer Res Treat 61: 1-12, 2000. (Pubitemid 30440545)
17. Wang-Rodriguez J, Urquidi V, Rivard A and Goodison S: Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status. Breast Cancer Res 5: R136-R143, 2003.
18. Gillespie MT, Thomas RJ, Pu ZY, Zhou H, Martin TJ and Findlay DM: Calcitonin receptors, bone sialoprotein and osteopontin are expressed in primary breast cancers. Int J Cancer 73: 812-815, 1997 (Pubitemid 127483032)
19. Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, Tenthorey J, Leiser A, Flores-Saaib R, Yu H, Azori M, Rutherford T, Schwartz PE and Mor G: Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 14: 1065-1072, 2008. (Pubitemid 351302552)
20. Mrochem J, Sodowski K, Deja R, Walaszek-Gruszka A, Wojcieszek A, Kołosza Z, Chmura A, Czernik E, Masłyk B, Bartnik W and Cnota W: Evaluation of selected serum protein markers as early detectors of ovarian cancer. Ginekol Pol 79: 271-275, 2008 (in Polish).
21. Nakae M, Iwamoto I, Fujino T, Maehata Y, Togami S, Yoshinaga M and Douchi T: Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer. J Obstet Gynaecol Res 32: 309-314, 2006. (Pubitemid 43800424)
22. Meinhold-Heerlein I, Bauerschlag D, Zhou Y, Sapinoso LM, Ching K, Frierson H Jr, Bräutigam K, Sehouli J, Stickeler E, Könsgen D, Hilpert F, von Kaisenberg CS, Pfisterer J, Bauknecht T, Jonat W, Arnold N and Hampton GM: An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma. Clin Cancer Res 13: 458-466, 2007. (Pubitemid 46225350)
23. Fredriksson S, Horecka J, Brustugun OT, Schlingemann J, Koong AC, Tibshirani R and Davis RW: Multiplexed proximity ligation assays to profile putative plasma biomarkers relevant to pancreatic and ovarian cancer. Clin Chem 54: 582-589, 2008. (Pubitemid 351348153)
24. Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, Hellstrom I, Mok SC, Liu J and Bast RC Jr.: Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 99: 267-277, 2005. (Pubitemid 41502830)
25. Brakora KA, Lee H, Yusuf R, Sullivan L, Harris A, Colella T and Seiden MV: Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer. Gynecol Oncol 93: 361-365, 2004. (Pubitemid 38507602)
26. Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, Steinhoff M, Messerlian G, DiSilvestro P, Granai CO and Bast RC Jr.: The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 108: 402-408, 2008. (Pubitemid 351174295)
27. Schorge JO, Drake RD, Lee H, Skates SJ, Rajanbabu R, Miller DS, Kim JH, Cramer DW, Berkowitz RS and Mok SC: Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. Clin Cancer Res 10: 3474-3478, 2004. (Pubitemid 38685455)
28. Kato N and Motoyama T: Overexpression of osteopontin in clear cell carcinoma of the ovary: close association with HNF-1beta expression. Histopathology 52: 682-688, 2008. (Pubitemid 351600043)
29. Maki M, Hirota S, Kaneko Y and Morohoshi T: Expression of osteopontin messenger RNA by macrophages in ovarian serous papillary cystadenocarcinoma. a possible association with calcification of psammoma bodies. Pathol Int 50: 531-535, 2000. (Pubitemid 30609860)
30. Briese J, Schulte HM, Bamberger CM, Löning T and Bamberger AM: Expression pattern of osteopontin in endometrial carcinoma: correlation with expression of the adhesion molecule CEACAM1. Int J Gynecol Pathol 25: 161-169, 2006. (Pubitemid 44620179)
31. Köbel M, Langhammer T, Hüttelmaier S, Schmitt WD, Kriese K, Dittmer J, Strauss HG, Thomssen C and Hauptmann S: Ezrin expression is related to poor prognosis in FIGO stage I endometrioid carcinomas. Mod Pathol 19: 581-587, 2006.
32. Cho H, Hong SW, Oh YJ, Kim MA, Kang ES, Lee JM, Kim SW, Kim SH, Kim JH, Kim YT and Lee K: Clinical significance of osteopontin expression in cervical cancer. J Cancer Res Clin Oncol 134: 909-917, 2008.
33. Wong YF, Cheung TH, Tsao GS, Lo KW, Yim SF, Wang VW, Heung MM, Chan SC, Chan LK, Ho TW, Wong KW, Li C, Guo Y, Chung TK and Smith DI: Genome-wide gene expression profiling of cervical cancer in Hong Kong women by oligonucleotide microarray. Int J Cancer 118: 2461-2469, 2006.
34. Tozawa K, Yamada Y, Kawai N, Okamura T, Ueda K and Kohri K: Osteopontin expression in prostate cancer and benign prostatic hyperplasia. Urol Int 62: 155-158, 1999. (Pubitemid 29473971)
35. Ramankulov A, Lein M, Kristiansen G, Meyer HA, Loening SA and Jung K: Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma. J Cancer Res Clin Oncol 133: 643-652, 2007. (Pubitemid 47077056)
36. Hotte SJ, Winquist EW, Stitt L, Wilson SM and Chambers AF: Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Cancer 95: 506-512, 2002. (Pubitemid 34810175)
37. Vergis R, Corbishley CM, Norman AR, Bartlett J, Jhavar S, Borre M, Heeboll S, Horwich A, Huddart R, Khoo V, Eeles R, Cooper C, Sydes M, Dearnaley D and Parker C: Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol 9: 342-351, 2008.
38. Castellano G, Malaponte G, Mazzarino MC, Figini M, Marchese F, Gangemi P, Travail S, Stivala F, Canevari S and Libra M: Activation of the osteopontin/matrix metalloproteinase-9 pathway correlates with prostate cancer progression. Clin Cancer Res 14: 7470-7480, 2008.
39. Matusan K, Dordevic G, Stipic D, Mozetic V and Lucin K: Osteopontin expression correlates with prognostic variables and survival in clear cell renal cell carcinoma. J Surg Oncol 94: 325-331, 2006. (Pubitemid 44330856)
40. Ramankulov A, Lein M, Kristiansen G, Loening SA and Jung K: Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer. Prostate 67: 330-340, 2007.
41. Nishie A, Masuda K, Otsubo M, Migita T, Tsuneyoshi M, Kohno K, Shuin T, Naito S, Ono M and Kuwano M: High expression of the CAP43 gene in infiltrating macrophages of human renal cell carcinomas. Clin Cancer Res 7: 2145-2151, 2001. (Pubitemid 32994855)
42. Ogbureke KU, Nikitakis NG, Warburton G, Ord RA, Sauk JJ, Waller JL and Fisher LW: Up-regulation of SIBLING proteins and correlation with cognate MMP expression in oral cancer. Oral Oncol 43: 920-932, 2007. (Pubitemid 47376828)
43. Katase N, Tamamura R, Gunduz M, Murakami J, Asaumi J, Tsukamoto G, Sasaki A and Nagatsuka H: A spindle cell carcinoma presenting with osseous metaplasia in the gingiva: a case report with immunohistochemical analysis. Head Face Med 4: 28, 2008.
44. Kusafuka K, Yamaguchi A, Kayano T and Takemura T: Expression of bone matrix proteins, osteonectin and osteopontin, in salivary pleomorphic adenomas. Pathol Res Pract 195: 733-739, 1999.
45. Shimada Y, Watanabe G, Kawamura J, Soma T, Okabe M, Ito T, Inoue H, Kondo M, Mori Y, Tanaka E and Imamura M: Clinical significance of osteopontin in esophageal squamous cell carcinoma: comparison with common tumor markers. Oncology 68: 285-292, 2005. (Pubitemid 41158988)
46. Zhang HZ, Liu JG, Wei YP, Wu C, Cao YK and Wang M: Expressions of RhoC and osteopontin in esophageal squamous carcinoma and association with the patients' prognosis. Nan Fang Yi Ke Da Xue Xue Bao 26: 1612-1615, 2006 (in Chinese).
47. Casson AG, Wilson SM, McCart JA, O'Malley FP, Ozcelik H, Tsao MS and Chambers AF: RAS mutation and expression of the RAS-regulated genes osteopontin and cathepsin L in human esophageal cancer. Int J Cancer 72: 739-745, 1997. (Pubitemid 27431513)
48. Gong YH, Sun LP and Yuan Y: Evaluation of serum pepsinogen I, II and osteopontin co-detection in gastric cancer screening. Zhonghua Zhong Liu Za Zhi 28: 691-693, 2006 (in Chinese).
49. Zhang DT, Yuan J, Yang L, Guo XN, Hao ZM, Han ZY, Wu KC and Fan DM: Osteopontin expression and its relation to invasion and metastases in gastric cancer. Zhonghua Zhong Liu Za Zhi 27: 167-169, 2005 (in Chinese).
50. Tang H, Wang J, Bai F, Zhai H, Gao J, Hong L, Xie H, Zhang F, Lan M, Yao W, Liu J, Wu K and Fan D: Positive correlation of osteopontin, cyclooxygenase-2 and vascular endothelial growth factor in gastric cancer. Cancer Invest 26: 60-67, 2008.
51. Yamagishi SI, Suzuki T, Ohkuro H and Yagihashi S: Ossifying gastric carcinoid tumor containing bone morphogenetic protein, osteopontin and osteonectin. J Endocrinol Invest 27: 870-873, 2004. (Pubitemid 40305519)
52. Rohde F, Rimkus C, Friederichs J, Rosenberg R, Marthen C, Doll D, Holzmann B, Siewert JR and Janssen KP: Expression of osteopontin, a target gene of de-regulated Wnt signaling, predicts survival in colon cancer. Int J Cancer 121: 1717-1723, 2007. (Pubitemid 47417288)
53. Carrer A, Zacchigna S, Balani A, Pistan V, Adami A, Porcelli F, Scaramucci M, Roseano M, Turoldo A, Prati MC, Dell'Omodarme M, de Manzini N and Giacca M: Expression profiling of angiogenic genes for the characterisation of colorectal carcinoma. Eur J Cancer 44: 1761-1769, 2008.
54. Galamb O: mRNA expression analysis and classification of colonic biopsy samples using oligonucleotide and cDNA microarray techniques. Orv Hetil 149: 1373-1377, 2008.
55. Koopmann J, Rosenzweig CN, Zhang Z, Canto MI, Brown DA, Hunter M, Yeo C, Chan DW, Breit SN and Goggins M: Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res 12: 442-446, 2006. (Pubitemid 43166133)
56. Ohike N, Sato M, Kawahara M, Ohyama S and Morohoshi T: Ductal adenocarcinoma of the pancreas with psammomatous calcification. Report of a case. JOP 9: 335-338, 2008. (Pubitemid 351864898)
57. Sedivy R, Peters K and Klöppel G: Osteopontin expression in ductal adenocarcinomas and undifferentiated carcinomas of the pancreas. Virchows Arch 446: 41-45, 2005. (Pubitemid 40179155)
58. Sedivy R, Kalipciyan M, Mazal PR, Wolf B, Wrba F, Karner-Hanusch J, Mühlbacher F and Mader RM: Osteoclast-like giant cell tumor in mucinous cystadenocarcinoma of the pancreas: an immunohistochemical and molecular analysis. Cancer Detect Prev 29: 8-14, 2005. (Pubitemid 40283493)
59. Bloomston M, Ellison EC, Muscarella P, Al-Saif O, Martin EW, Melvin WS and Frankel WL: Stromal osteonectin overexpression is associated with poor outcome in patients with ampullary cancer. Ann Surg Oncol 14: 211-217, 2007. (Pubitemid 44954291)
60. Pan HW, Ou YH, Peng SY, Liu SH, Lai PL, Lee PH, Sheu JC, Chen CL and Hsu HC: Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer 98: 119-127, 2003.
61. Xie H, Song J, Du R, Liu K, Wang J, Tang H, Bai F, Liang J, Lin T, Liu J and Fan D: Prognostic significance of osteopontin in hepatitis B virus-related hepatocellular carcinoma. Dig Liver Dis 39: 167-172, 2007. (Pubitemid 46117934)
62. Peng SY, Ou YH, Chen WJ, Li HY, Liu SH, Pan HW, Lai PL, Jeng YM, Chen DC and Hsu HC: Aberrant expressions of annexin A10 short isoform, osteopontin and alpha-fetoprotein at chromosome 4q cooperatively contribute to progression and poor prognosis of hepatocellular carcinoma. Int J Oncol 26: 1053-1061, 2005.
63. Yang GH, Fan J, Xu Y, Qiu SJ, Yang XR, Shi GM, Wu B, Dai Z, Liu YK, Tang ZY and Zhou J: Osteopontin combined with CD44, a novel prognostic biomarker for patients with hepatocellular carcinoma undergoing curative resection. Oncologist 13: 1155-1165, 2008.
64. Korita PV, Wakai T, Shirai Y, Matsuda Y, Sakata J, Cui X, Ajioka Y and Hatakeyama K: Overexpression of osteopontin independently correlates with vascular invasion and poor prognosis in patients with hepatocellular carcinoma. Hum Pathol 39: 1777-1783, 2008.
65. Kim J, Ki SS, Lee SD, Han CJ, Kim YC, Park SH, Cho SY, Hong YJ, Park HY, Lee M, Jung HH, Lee KH and Jeong SH: Elevated plasma osteopontin levels in patients with hepatocellular carcinoma. Am J Gastroenterol 101: 2051-2059, 2006. (Pubitemid 44337631)
66. Lee YC, Pan HW, Peng SY, Lai PL, Kuo WS, Ou YH and Hsu HC: Overexpression of tumour-associated trypsin inhibitor (TATI) enhances tumour growth and is associated with portal vein invasion, early recurrence and a stage-independent prognostic factor of hepatocellular carcinoma. Eur J Cancer 43: 736-744, 2007.
67. Zhang H, Ren N, Ye QH, Sun HC, Wang L, Liu YK, Tang ZY and Qin LX: The prognostic significance of preoperative plasma level of osteopontin in combination with intercellular adhesion molecule-1 for patients with hepatocellular carcinoma. Zhonghua Wai Ke Za Zhi 43: 985-988, 2005 (in Chinese)
68. Iso Y, Sawada T, Okada T and Kubota K: Loss of E-cadherin mRNA and gain of osteopontin mRNA are useful markers for detecting early recurrence of HCV-related hepatocellular carcinoma. J Surg Oncol 92: 304-311, 2005. (Pubitemid 41779288)
69. Yuan RH, Jeng YM, Chen HL, Lai PL, Pan HW, Hsieh FJ, Lin CY, Lee PH and Hsu HC: Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J Pathol 209: 549-558, 2006. (Pubitemid 44194570)
70. Luo JH, Ren B, Keryanov S, Tseng GC, Rao UN, Monga SP, Strom S, Demetris AJ, Nalesnik M, Yu YP, Ranganathan S and Michalopoulos GK: Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. Hepatology 44: 1012-1024, 2006. (Pubitemid 46489565)
71. Le QT, Chen E, Salim A, Cao H, Kong CS, Whyte R, Donington J, Cannon W, Wakelee H, Tibshirani R, Mitchell JD, Richardson D, O'Byrne KJ, Koong AC and Giaccia AJ: An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res 12: 1507-1514, 2006.
72. Chang YS, Kim HJ, Chang J, Ahn CM, Kim SK and Kim SK: Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer. Lung Cancer 57: 373-380, 2007. (Pubitemid 47285428)
73. Mack PC, Redman MW, Chansky K, Williamson SK, Farneth NC, Lara PN Jr, Franklin WA, Le QT, Crowley JJ, Gandara DR and SWOG: Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J Clin Oncol 26: 4771-4776, 2008.
74. Schneider S, Yochim J, Brabender J, Uchida K, Danenberg KD, Metzger R, Schneider PM, Salonga D, Hölscher AH and Danenberg PV: Osteopontin but not osteonectin messenger RNA expression is a prognostic marker in curatively resected non-small cell lung cancer. Clin Cancer Res 10: 1588-1596, 2004. (Pubitemid 38435547)
75. Frey AB, Wali A, Pass H and Lonardo F: Osteopontin is linked to p65 and MMP-9 expression in pulmonary adenocarcinoma but not in malignant pleural mesothelioma. Histopathology 50: 720-726, 2007. (Pubitemid 46683928)
76. Zhang J, Takahashi K, Takahashi F, Shimizu K, Ohshita F, Kameda Y, Maeda K, Nishio K and Fukuchi Y: Differential osteopontin expression in lung cancer. Cancer Lett 171: 215-222, 2001. (Pubitemid 32772809)
77. Shijubo N, Uede T, Kon S, Maeda M, Segawa T, Imada A, Hirasawa M and Abe S: Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. Am J Respir Crit Care Med 160: 1269-1273, 1999. (Pubitemid 29487470)
78. Creaney J, Yeoman D, Demelker Y, Segal A, Musk AW, Skates SJ and Robinson BW: Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J Thorac Oncol 3: 851-857, 2008.
79. Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, Grégoire M, Porte H, Copin MC and Lassalle P: Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res 13: 2928-2935, 2007. (Pubitemid 46850705)
80. Le QT, Kong C, Lavori PW, O'byrne K, Erler JT, Huang X, Chen Y, Cao H, Tibshirani R, Denko N, Giaccia AJ and Koong AC: Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 69: 167-175, 2007. (Pubitemid 47247510)
81. Nordsmark M, Eriksen JG, Gebski V, Alsner J, Horsman MR and Overgaard J: Differential risk assessments from five hypoxia specific assays: The basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients. Radiother Oncol 83: 389-397, 2007. (Pubitemid 46907981)
82. Bache M, Reddemann R, Said HM, Holzhausen HJ, Taubert H, Becker A, Kuhnt T, Hänsgen G, Dunst J and Vordermark D: Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1alpha-related markers, and hemoglobin levels. Int J Radiat Oncol Biol Phys 66: 1481-1487, 2006.
83. Staibano S, Merolla F, Testa D, Iovine R, Mascolo M, Guarino V, Castellone MD, Di Benedetto M, Galli V, Motta S, Melillo RM, De Rosa G, Santoro M and Celetti A: OPN/CD44v6 overexpression in laryngeal dysplasia and correlation with clinical outcome. Br J Cancer 97: 1545-1551, 2007. (Pubitemid 350175855)
84. Shimizu S, Tsukada J, Sugimoto T, Kikkawa N, Sasaki K, Chazono H, Hanazawa T, Okamoto Y and Seki N: Identification of a novel therapeutic target for head and neck squamous cell carcinomas: a role for the neurotensin- neurotensin receptor 1 oncogenic signaling pathway. Int J Cancer 123: 1816-1823, 2008.
85. Li Y, Lu Y, Ceng Y and Yang X: Expression of connective tissue growth factor (CTGF), osteopontin (OPN) and clinical significances in the laryngeal squamous cell carcinoma tissues. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 21: 121-123, 2007 (in Chinese).
86. Eto M, Kodama S, Nomi N, Uemura N and Suzuki M: Clinical significance of elevated osteopontin levels in head and neck cancer patients. Auris Nasus Larynx 34: 343-346, 2007. (Pubitemid 46829719)
87. Said HM, Hagemann C, Staab A, Stojic J, Kühnel S, Vince GH, Flentje M, Roosen K and Vordermark D: Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in vivo. Radiother Oncol 83: 398-405, 2007. (Pubitemid 46907985)
88. Takano S, Tsuboi K, Tomono Y, Mitsui Y and Nose T: Tissue factor, osteopontin, alphavbeta3 integrin expression in microvasculature of gliomas associated with vascular endothelial growth factor expression. Br J Cancer 82: 1967-1973, 2000. (Pubitemid 30326458)
89. Colin C, Baeza N, Bartoli C, Fina F, Eudes N, Nanni I, Martin PM, Ouafik L and Figarella-Branger D: Identification of genes differentially expressed in glioblastoma versus pilocytic astrocytoma using suppression subtractive hybridization. Oncogene 25: 2818-2826, 2006.
90. Cummings TJ, Hulette CM, Bigner SH, Riggins GJ and McLendon RE: HAM56-immunoreactive macrophages in untreated infiltrating gliomas. Arch Pathol Lab Med 125: 637-641, 2001. (Pubitemid 32429810)
91. Alonso SR, Tracey L, Ortiz P, Pérez-Gómez B, Palacios J, Pollán M, Linares J, Serrano S, Sáez-Castillo AI, Sánchez L, Pajares R, Sánchez-Aguilera A, Artiga MJ, Piris MA and Rodríguez-Peralto JL: A high-throughput study in melanoma identifies epithelial mesenchymal transition as a major determinant of metastasis. Cancer Res 67: 3450-3460, 2007. (Pubitemid 46724886)
92. Bachmann IM, Ladstein RG, Straume O, Naumov GN and Akslen LA: Tumor necrosis is associated with increased alphavbeta3 integrin expression and poor prognosis in nodular cutaneous melanomas. BMC Cancer 8: 362, 2008.
93. Del Sordo R, Cavaliere A and Sidoni A: Basal cell carcinoma with matrical differentiation: expression of beta-catenin (corrected) and osteopontin. Am J Dermatopathol 29: 470-474, 2007. (Pubitemid 47463858)
94. Oler G, Camacho CP, Hojaij FC, Michaluart P Jr., Riggins GJ and Cerutti JM: Gene expression profiling of papillary thyroid carcinoma identifies transcripts correlated with BRAF mutational status and lymph node metastasis. Clin Cancer Res 14: 4735-4742, 2008.
95. Guarino V, Faviana P, Salvatore G, Castellone MD, Cirafici AM, De Falco V, Celetti A, Giannini R, Basolo F, Melillo RM and Santoro M: Osteopontin is overexpressed in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness. J Clin Endocrinol Metab 90: 5270-5278, 2005. (Pubitemid 41262285)
96. Tunio GM, Hirota S, Nomura S and Kitamura Y: Possible relation of osteopontin to development of psammoma bodies in human papillary thyroid cancer. Arch Pathol Lab Med 122: 1087-1090, 1998. (Pubitemid 29009401)
97. Sulzbacher I, Birner P, Trieb K, Lang S and Chott A: Expression of osteopontin and vascular endothelial growth factor in benign and malignant bone tumors. Virchows Arch 441: 345-349, 2002. (Pubitemid 36015597)
98. Carlos-Bregni R, Contreras E, Hiraki KR, Vargas PA, León JE and de Almeida OP: Epithelioid osteosarcoma of the mandible: a rare case with unusual immunoprofile. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 105: e47-e52, 2008.
99. Wong IH, Chan AT and Johnson PJ: Quantitative analysis of circulating tumor cells in peripheral blood of osteosarcoma patients using osteoblast-specific messenger RNA markers: a pilot study. Clin Cancer Res 6: 2183-2188, 2000. (Pubitemid 30399183)
100. Dalla-Torre CA, Yoshimoto M, Lee CH, Joshua AM, de Toledo SR, Petrilli AS, Andrade JA, Chilton-MacNeill S, Zielenska M and Squire JA: Effects of THBS3, SPARC and SPP1 expression on biological behavior and survival in patients with osteosarcoma. BMC Cancer 6: 237, 2006.
101. Sando N, Oka K, Moriya T, Saito H, Nagakura S, Mori N, Suzuki T, Ueki H and Ohtani H: Osteosarcoma arising in the breast. APMIS 114: 581-587, 2006.
102. Benoist-Lasselin C, de Margerie E, Gibbs L, Cormier S, Silve C, Nicolas G, LeMerrer M, Mallet JF, Munnich A, Bonaventure J, Zylberberg L and Legeai-Mallet L: Defective chondrocyte proliferation and differentiation in osteochondromas of MHE patients. Bone 39: 17-26, 2006. (Pubitemid 43831772)
103. Hoshi N, Sugino T and Suzuki T: Regular expression of osteopontin in granular cell tumor: distinctive feature among Schwannian cell tumors. Pathol Int 55: 484-490, 2005. (Pubitemid 41097849)
104. Bramwell VH, Tuck AB, Wilson SM, Stitt LW, Cherian AK, Rorke SC, Al-Katib W, Postenka CO and Chambers AF: Expression of osteopontin and HGF/MET in adult soft tissue tumors. Cancer Biol Ther 4: 1336-1341, 2005. (Pubitemid 43131177)
105. Gaumann A, Petrow P, Mentzel T, Mayer E, Dahm M, Otto M, Kirkpatrick CJ and Kriegsmann J: Osteopontin expression in primary sarcomas of the pulmonary artery. Virchows Arch 439: 668-674, 2001. (Pubitemid 33071206)
106. Dizdar O, Barista I, Kalyoncu U, Karadag O, Hascelik G, Cila A, Pinar A, Celik I, Kars A and Tekuzman G: Biochemical markers of bone turnover in diagnosis of myeloma bone disease. Am J Hematol 82: 185-191, 2007. (Pubitemid 46363783)
107. Standal T, Hjorth-Hansen H, Rasmussen T, Dahl IM, Lenhoff S, Brenne AT, Seidel C, Baykov V, Waage A, Børset M, Sundan A and Hjertner O: Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma. Haematologica 89: 174-182, 2004. (Pubitemid 38796491)
108. Yuan RH, Jeng YM, Chen HL, Lai PL, Pan HW, Hsieh FJ, Lin CY, Lee PH and Hsu HC: Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinom. J Pathol 209: 549-558, 2006. (Pubitemid 44194570)
109. Tuck AB, Arsenault DM, O'Malley FP, Hota C, Ling MC, Wilson SM and Chambers AF: Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene 18: 4237-4246, 1999. (Pubitemid 29377854)
110. Kawakami T, Shimizu T, Kimura A, Hasegawa H, Siar CH, Ng KH, Nagatsuka H, Nagai N and Kanda H: Immunohistochemical examination of cytological differentiation in osteosarcomas. Eur J Med Res 10: 475-479, 2005. (Pubitemid 41723595)
111. Bautista DS, Denstedt J, Chambers AF and Harris JF: Low-molecular-weight variants of osteopontin generated by serine proteinases in urine of patients with kidney stones. J Cell Biochem 61: 402-409, 1996. (Pubitemid 26170818)
112. Zhao L, Li T, Wang Y, Pan Y, Ning H, Hui X, Xie H, Wang J, Han Y, Liu Z and Fan D: Elevated plasma osteopontin level is predictive of cirrhosis in patients with hepatitis B infection. Int J Clin Pract 62: 1056-1062, 2008. (Pubitemid 351793583)
113. Zdzisinska B, Bojarska-Junak A, Dmoszynska A and Kandefer-Szerszen M: Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells. Arch Immunol Ther Exp (Warsz) 56: 207-221, 2008.
114. Mok SC, Chao J, Skates S, Wong K, Yiu GK, Muto MG, Berkowitz RS and Cramer DW: Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J Natl Cancer Inst 93: 1458-1464, 2001. (Pubitemid 32982674)
115. O'Neill CJ, Deavers MT, Malpica A, Foster H and McCluggage WG: An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms. Am J Surg Pathol 29: 1034-1041, 2005. (Pubitemid 41045547)
116. Hirota S, Asada H, Kohri K, Tsukamoto Y, Ito A, Yoshikawa K, Xu Z, Nomura S and Kitamura Y: Possible role of osteopontin in deposition of calcium phosphate in human pilomatricomas. J Invest Dermatol 105: 138-142, 1995.
117. Matusan K, Dordevic G, Mozetic V and Lucin K: Expression of osteopontin and CD44 molecule in papillary renal cell tumors. Pathol Oncol Res 11: 108-113, 2005. (Pubitemid 41039448)